Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4556287 | 0.98 | TLR7 (0.42) | TLR7TLR8 | |
| SCHEMBL25338771 | 0.98 | TLR7 (0.42) | TLR7TLR8 | |
| SCHEMBL3275133 | 0.94 | TLR7 (0.41) | TLR7TLR8 | |
| SCHEMBL4238527 | 0.92 | TLR7 (0.45) | TLR7TLR8 | |
| SCHEMBL4621585 | 0.91 | TLR7 (0.41) | TLR7TLR8 | |
| SCHEMBL143656 | 0.89 | TLR7 (0.52) | TLR7TLR8 | |
| SCHEMBL4019917 | 0.89 | TLR7 (0.50) | TLR7TLR8 | |
| SCHEMBL147063 | 0.88 | TLR7 (0.51) | TLR7TLR8 | |
| SCHEMBL31092872 | 0.88 | TLR7 (0.51) | TLR7TLR8 | |
| SCHEMBL149093 | 0.87 | TLR7 (0.52) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357369-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-11-09 | — | — | US | disclosed |
| EP-4159232-A1 | RSV IMMUNIZATION REGIMEN | GlaxoSmithKline Biologicals S.A. (BE) | 2023-04-05 | — | — | EP | disclosed |
| EP-4144368-A1 | RSV IMMUNIZATION REGIMEN | GlaxoSmithKline Biologicals S.A. (BE) | 2023-03-08 | — | — | EP | disclosed |
| US-20190275141-A1 | RSV IMMUNIZATION REGIMEN | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2019-09-12 | — | — | US | disclosed |
| US-10342862-B2 | RSV immunization regimen | GLAXOSMITHKLINE BIOLOGICALS, SA (BE) | 2019-07-09 | — | — | US | disclosed |
| EP-2707385-B1 | PRE-FUSION RSV F ANTIGENS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357369-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | RNASEL, TIMCC, RNGTT | TLR7 349/4885TLR8 1489/4885 |
| US-10342862-B2 | RSV immunization regimen | IL5, IL15, IFNG | TLR7 48/4885TLR8 77/4885 |
| US-20190275141-A1 | RSV IMMUNIZATION REGIMEN | IL5, IL15, IFNG | TLR7 48/4885TLR8 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.